CARB-X
Accelerate a diverse portfolio of at least 20 high-quality antibacterial products towards clinical development leveraging $250 million in BARDA funds with matching funds from the Wellcome Trust and the AMR Centre.
CARB-X
Founded:
2016-07-01
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API Google Analytics Google Tag Manager WordPress Wordpress Plugins Global Site Tag Nginx
Similar Organizations
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Mast Therapeutics
Mast Therapeutics is a biopharmaceutical company developing novel, clinical-stage therapies for serious or life-threatening diseases.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Employees Featured
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-04-04 | Clarametyx Biosciences | CARB-X investment in Grant - Clarametyx Biosciences | 3.89 M USD |
| 2021-08-05 | Vaxcyte | CARB-X investment in Grant - Vaxcyte | 3.2 M USD |
| 2021-06-08 | Accelerate Diagnostics | CARB-X investment in Grant - Accelerate Diagnostics | 578 K USD |
| 2021-06-01 | BioVersys | CARB-X investment in Grant - BioVersys | 4.35 M USD |
| 2021-05-27 | SNIPR Biome | CARB-X investment in Grant - SNIPR Biome | 10.2 M USD |
| 2021-05-19 | Basilea Pharmaceutica | CARB-X investment in Grant - Basilea Pharmaceutica | 2.7 M USD |
| 2021-05-18 | Summit Therapeutics | CARB-X investment in Grant - Summit Therapeutics | 4.1 M USD |
| 2021-05-10 | SpeeDx | CARB-X investment in Grant - SpeeDx | 1.8 M USD |
| 2021-04-27 | GenomeKey | CARB-X investment in Grant - GenomeKey | 9.5 M USD |
| 2021-04-20 | Baebies | CARB-X investment in Grant - Baebies | 11.6 M USD |
More informations about "CARB-X"
Overview - Carb-X
How CARB-X works. CARB-X fills a critical gap to help stem this crisis. Beginning with competitive funding calls to address unmet medical needs, CARB-X provides non-dilutive funding as well as scientific, regulatory and business support to …See details»
CARB-X launches new funding round to fill major R&D gaps in …
Mar 6, 2024 CARB-X is funded in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical …See details»
CARB-X - Wikipedia
Bacteria are constantly evolving to evade death. Even the most powerful "last resort" drugs are becoming less effective due to resistance. Without an arsenal of effective antibiotics to treat infections, modern medical procedures – such as chemotherapy and surgeries – are more risky and put patients' lives at risk. Approximately 1.27 million people died globally in 2019 due to drug-resistant bacterial infections. CARB-X supports projects that are focused on the most dangerou…See details»
Government of Canada makes important investment to fight …
Combating Antibiotic-Resistant Bacteria …
CARB-X is funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the United States Department of Health and Human …See details»
CARB-X and CHAI partner to tackle AMR, and …
5 days ago About CARB-X. CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) is a global non-profit partnership dedicated to supporting early-stage antibacterial research and development to address the …See details»
GARDP and CARB-X welcome renewed commitment by …
Jul 8, 2022 CARB-X supports the world’s largest and most innovative pipeline of preclinical and early-stage development products against antibiotic-resistant infections. CARB-X is headquartered at Boston University School of Law. For …See details»
Inside CARB-X: can this new model for research fix a broken …
Nov 22, 2017 CARB-X was founded last year, in response to the US Government’s 2015 Combating Antibiotic Resistant Bacteria initiative, with the goal of fixing this market failure. …See details»
Our Strategy - Carb-X
While CARB-X grants are non-dilutive, we require our product developers to have solid assets that have demonstrated private investment in their project. The result is an innovative pipeline that is growing. Since 2017, the year of our first …See details»
CARB-X Funds 100th Project—a Milestone for BU …
Mar 6, 2024 The World Health Organization has flagged the resistance of bacteria like Klebsiella pneumoniae to antibiotics as a major concern. BU-based CARB-X, which just funded its 100th project, aims to accelerate the …See details»
Novo Nordisk Foundation partners with CARB-X to fight drug …
Jan 9, 2024 About CARB-X. CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) is a global non-profit partnership dedicated to supporting early …See details»
Innovation in Antimicrobial Resistance: The CARB-X Perspective
With up to US $500 million to invest, the mission of CARB-X is to identify, select, and fund, in a nondilutive manner, high quality and differentiated science from around the world. CARB-X …See details»
Accelerating global innovation to address antibacterial resistance ...
Jul 29, 2016 CARB-X: accelerating antibacterial innovation. CARB-X is a global accelerator, designed to provide significant research funding, research support services and business …See details»
CARB-X to partner with Clinton Health Access Initiative on
5 days ago The 2-year partnership between CARB-X and CHAI will evaluate the clinical need and address market barriers for diagnostic, therapeutic, and preventive interventions for …See details»
CARB-X and CHAI partner to sharpen AMR response, tackle …
About CARB-X. CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) is a global non-profit partnership dedicated to supporting early-stage antibacterial research …See details»
CARB-X announces funding for global scientists racing to
Jul 24, 2017 CARB-X is the world's largest public-private partnership devoted to early stage antibacterial R&D. Funded by BARDA and Wellcome, with in-kind support from NIAID, we will …See details»
CARB-X Collaborative Hub for Early Antibiotic Discovery
The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is a global initiative dedicated to protecting humankind from the most serious bacterial threats to human …See details»
CARB-X 2021-22 annual report launched today - Carb-X
Apr 27, 2023 CARB-X accelerates new products to address the global threat of antimicrobial resistance (BOSTON: April 27, 2023) – CARB-X published its 2021-2022 annual report …See details»
CARB-X - Institute for Life Science Entrepreneurship
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is one of the largest and most promising global non-profit partnerships addressing AMR by supporting the …See details»
CARB-X 2020-21 annual report: CARB-X surpasses all goals in first …
Oct 12, 2021 CARB-X continues to prepare the world against antibiotic-resistant bacteria (BOSTON: October 12, 2021) – CARB-X closed its fifth fiscal year on July 31, 2021 with …See details»